Cargando…

Plasmonic Fluor-Enhanced Antigen Arrays for High-Throughput, Serological Studies of SARS-CoV-2

[Image: see text] Serological testing for acute infection or prior exposure is critical for patient management and coordination of public health decisions during outbreaks. Current methods have several limitations, including variable performance, relatively low analytical and clinical sensitivity, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Qavi, Abraham J., Wu, Chao, Lloyd, Matthew, Zaman, Mohammad Mahabub-Uz, Luan, Jingyi, Ballman, Claire, Leung, Daisy W., Crick, Scott L., Farnsworth, Christopher W., Amarasinghe, Gaya K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344907/
https://www.ncbi.nlm.nih.gov/pubmed/35867632
http://dx.doi.org/10.1021/acsinfecdis.2c00086
_version_ 1784761316637933568
author Qavi, Abraham J.
Wu, Chao
Lloyd, Matthew
Zaman, Mohammad Mahabub-Uz
Luan, Jingyi
Ballman, Claire
Leung, Daisy W.
Crick, Scott L.
Farnsworth, Christopher W.
Amarasinghe, Gaya K.
author_facet Qavi, Abraham J.
Wu, Chao
Lloyd, Matthew
Zaman, Mohammad Mahabub-Uz
Luan, Jingyi
Ballman, Claire
Leung, Daisy W.
Crick, Scott L.
Farnsworth, Christopher W.
Amarasinghe, Gaya K.
author_sort Qavi, Abraham J.
collection PubMed
description [Image: see text] Serological testing for acute infection or prior exposure is critical for patient management and coordination of public health decisions during outbreaks. Current methods have several limitations, including variable performance, relatively low analytical and clinical sensitivity, and poor detection due to antigenic drift. Serological methods for SARS-CoV-2 detection for the ongoing COVID-19 pandemic suffer from several of these limitations and serves as a reminder of the critical need for new technologies. Here, we describe the use of ultrabright fluorescent reagents, Plasmonic Fluors, coupled with antigen arrays that address a subset of these limitations. We demonstrate its application using patient samples in SARS-CoV-2 serological assays. In our multiplexed assay, SARS-CoV-2 antigens were spotted into 48-plex arrays within a single well of a 96-well plate and used to evaluate remnant laboratory samples of SARS-CoV-2 positive patients. Signal-readout was performed with Auragent Bioscience’s Empower microplate reader, and microarray analysis software. Sample volumes of 1 μL were used. High sensitivity of the Plasmonic Fluors combined with the array format enabled us to profile patient serological response to eight distinct SARS-CoV-2 antigens and evaluate responses to IgG, IgM, and IgA. Sensitivities for SARS-CoV-2 antigens during the symptomatic state ranged between 72.5 and 95.0%, specificity between 62.5 and 100%, and the resulting area under the curve values between 0.76 and 0.97. Together, these results highlight the increased sensitivity for low sample volumes and multiplex capability. These characteristics make Plasmonic Fluor-enhanced antigen arrays an attractive technology for serological studies for the COVID-19 pandemic and beyond.
format Online
Article
Text
id pubmed-9344907
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-93449072022-08-03 Plasmonic Fluor-Enhanced Antigen Arrays for High-Throughput, Serological Studies of SARS-CoV-2 Qavi, Abraham J. Wu, Chao Lloyd, Matthew Zaman, Mohammad Mahabub-Uz Luan, Jingyi Ballman, Claire Leung, Daisy W. Crick, Scott L. Farnsworth, Christopher W. Amarasinghe, Gaya K. ACS Infect Dis [Image: see text] Serological testing for acute infection or prior exposure is critical for patient management and coordination of public health decisions during outbreaks. Current methods have several limitations, including variable performance, relatively low analytical and clinical sensitivity, and poor detection due to antigenic drift. Serological methods for SARS-CoV-2 detection for the ongoing COVID-19 pandemic suffer from several of these limitations and serves as a reminder of the critical need for new technologies. Here, we describe the use of ultrabright fluorescent reagents, Plasmonic Fluors, coupled with antigen arrays that address a subset of these limitations. We demonstrate its application using patient samples in SARS-CoV-2 serological assays. In our multiplexed assay, SARS-CoV-2 antigens were spotted into 48-plex arrays within a single well of a 96-well plate and used to evaluate remnant laboratory samples of SARS-CoV-2 positive patients. Signal-readout was performed with Auragent Bioscience’s Empower microplate reader, and microarray analysis software. Sample volumes of 1 μL were used. High sensitivity of the Plasmonic Fluors combined with the array format enabled us to profile patient serological response to eight distinct SARS-CoV-2 antigens and evaluate responses to IgG, IgM, and IgA. Sensitivities for SARS-CoV-2 antigens during the symptomatic state ranged between 72.5 and 95.0%, specificity between 62.5 and 100%, and the resulting area under the curve values between 0.76 and 0.97. Together, these results highlight the increased sensitivity for low sample volumes and multiplex capability. These characteristics make Plasmonic Fluor-enhanced antigen arrays an attractive technology for serological studies for the COVID-19 pandemic and beyond. American Chemical Society 2022-07-22 2022-08-12 /pmc/articles/PMC9344907/ /pubmed/35867632 http://dx.doi.org/10.1021/acsinfecdis.2c00086 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Qavi, Abraham J.
Wu, Chao
Lloyd, Matthew
Zaman, Mohammad Mahabub-Uz
Luan, Jingyi
Ballman, Claire
Leung, Daisy W.
Crick, Scott L.
Farnsworth, Christopher W.
Amarasinghe, Gaya K.
Plasmonic Fluor-Enhanced Antigen Arrays for High-Throughput, Serological Studies of SARS-CoV-2
title Plasmonic Fluor-Enhanced Antigen Arrays for High-Throughput, Serological Studies of SARS-CoV-2
title_full Plasmonic Fluor-Enhanced Antigen Arrays for High-Throughput, Serological Studies of SARS-CoV-2
title_fullStr Plasmonic Fluor-Enhanced Antigen Arrays for High-Throughput, Serological Studies of SARS-CoV-2
title_full_unstemmed Plasmonic Fluor-Enhanced Antigen Arrays for High-Throughput, Serological Studies of SARS-CoV-2
title_short Plasmonic Fluor-Enhanced Antigen Arrays for High-Throughput, Serological Studies of SARS-CoV-2
title_sort plasmonic fluor-enhanced antigen arrays for high-throughput, serological studies of sars-cov-2
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9344907/
https://www.ncbi.nlm.nih.gov/pubmed/35867632
http://dx.doi.org/10.1021/acsinfecdis.2c00086
work_keys_str_mv AT qaviabrahamj plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2
AT wuchao plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2
AT lloydmatthew plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2
AT zamanmohammadmahabubuz plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2
AT luanjingyi plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2
AT ballmanclaire plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2
AT leungdaisyw plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2
AT crickscottl plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2
AT farnsworthchristopherw plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2
AT amarasinghegayak plasmonicfluorenhancedantigenarraysforhighthroughputserologicalstudiesofsarscov2